Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- FDX +13.9%
Other news:
- RIVN +41% (establishing JV with Volkwagen; discloses convertible promissory note purchase agreement)
- SVRA +31.1% (announces molgramostim nebulizer solution (molgramostim) achieved statistical significance for primary endpoint and multiple secondary endpoints in IMPALA-2, a pivotal phase 3 clinical trial in autoimmune pulmonary alveolar proteinosis)
- TGLS +11.1% (conducting review of strategic alternatives; reiterates FY24 outlook)
- ANNX +9.2% (presents Phase 3 results)
- VSTO +8.5% (MNC Capital increases all-cash offer to acquire Vista Outdoor to $42/share; CFIUS clears sale of The Kinetic Group to CSG )
- LCID +5.2% (trades in sympathy with RIVN)
- PL +4.8% (committed to a plan to reduce its global headcount by approximately 180 employees; reaffirms guidance)
- FUN +3.5% (Cedar Fair & and Six Flags (SIX) announce the satisfaction of regulatory conditions for the proposed merger of equals)
- KNSA +2% (enters into supply agreement with Samsung Biologics)
- MEI +1.9% (appoints new CEO)
- GPS +1.9% (positive Barron's article)
- HITI +1.4% (to acquire Mississauga retail cannabis store)
- EARN +1.4% (determined to more closely align the management fee arrangement between the Company and the Manager with the advisory fee structures of CLO-focused registered closed-end funds)
- NTLA +1.4% (appointment of Edward Dulac as CFO)
- ARGX +1.2% (highlights autoimmune pipeline)
- ACIC +1% (enters 5-year extension of MGA Agreement)
- LYEL +1% (reports dose-dependent clinical activity from phase 1 trial of lyl797, a ror1-targeted car-t cell product candidate enhanced with its proprietary anti-exhaustion technology)
- ENVX +1% (signs MOU with battery pack manufacturer Elentec)
Analyst comments:
- ERO +1.4% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- DLR +1.2% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- AAPL +0.9% (upgraded to Buy from Neutral at Rosenblatt)